LCID
Lucid Group, Inc.
LCID lost money over the past year, so it has no meaningful PE right now. Analysts expect losses to shrink, though they disagree widely on how much.
SORA
AsiaStrategy
There isn't enough reported data to score SORA yet.
LCID Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Unavailable |
LCID's revenue is currently healthy, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
SORA Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Weak |
SORA's profitability is currently healthy, but its balance sheet is weak. There isn't enough data to rate its revenue and cash flow.
LCID PE Valuation
LCID has no meaningful PE right now: it lost money over the past year.
SORA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 3.9x | $1.94 | -20% |
| Fair | 4.7x | $2.34 | -3.7% |
| Current | 4.9x | $2.43 | — |
| Expensive | 5.1x | $2.57 | +5.9% |
Historical ranges are pointers, not guarantees.
SORA's PE is 4.8x, but its earnings don't support one, so it isn't a reliable read right now.
LCID Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect LCID's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
SORA Forward outlook
There aren't enough analyst estimates for SORA to show an outlook.
LCID Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.08 | -$2.57 |
| Q2 2026 | -$13.65 | -$2.35 |
| Q1 2026 | -$13.15 | -$1.25 |
| Q4 2025 | -$12.09 | +$0.41 |
| Q3 2025 | -$10.51 | +$2.49 |
| Q2 2025 | -$11.30 | +$0.40 |
| Q1 2025 | -$11.90 | +$0.40 |
| Q4 2024 | -$12.50 | +$1.10 |
LCID is still losing money, but less than at its worst: $13.08 per share over the past year, against $16.50 at its worst in mid-2023.
SORA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2025 | $0.50 | +$0.50 |
SORA and LCID do not have enough comparable growth data to identify a winner.
LCID Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $350.3M | +4.1% |
| Q2 2026 | $405.3M | +56% |
| Q1 2026 | $282.5M | +20% |
| Q4 2025 | $522.7M | +123% |
| Q3 2025 | $336.6M | +68% |
| Q2 2025 | $259.4M | +29% |
| Q1 2025 | $235M | +36% |
| Q4 2024 | $234.5M | +49% |
LCID has the edge over SORA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -245% | +35 points |
| Q2 2026 | -267% | +43 points |
| Q1 2026 | -350% | -56 points |
| Q4 2025 | -204% | +109 points |
| Q3 2025 | -280% | +105 points |
| Q2 2025 | -310% | +83 points |
| Q1 2025 | -294% | +128 points |
| Q4 2024 | -313% | +156 points |
LCID's operating margin was −245% last quarter, up 35 points from the same quarter a year ago, near the top of its range since 2020.
SORA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $6.6M | -63% |
| Q4 2024 | $17.6M | +141% |
| Q4 2023 | $7.3M | +2.6% |
| Q2 2023 | $11.5M | +62% |
LCID has the edge over SORA in the latest year-over-year revenue comparison.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -16% | -20 points |
| Q2 2025 | -12% | -13 points |
| Q4 2024 | 1.3% | -0.1 points |
| Q4 2023 | 4% | N/A |
| Q2 2023 | 4% | N/A |
| Q4 2022 | 1.4% | N/A |
| Q2 2022 | 1.4% | N/A |
SORA's operating margin was −16% last quarter, down 20 points from the same quarter a year ago, near the bottom of its range since 2022.
LCID Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1B | -$84.2M |
| Q2 2026 | -$1.5B | -$463.2M |
| Q1 2026 | -$1.4B | -$849M |
| Q4 2025 | -$1.2B | -$417.1M |
| Q3 2025 | -$955.5M | -$333M |
| Q2 2025 | -$1B | -$271.6M |
| Q1 2025 | -$589.9M | +$125.1M |
| Q4 2024 | -$824.8M | -$77.6M |
LCID has burned cash in almost every quarter: −$5.2B over the past year, against −$3.4B the year before.
SORA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2023 | $1.4M | +$2.5M |
| Q2 2023 | -$86K | +$993.3K |
SORA and LCID do not have enough comparable growth data to identify a winner.
LCID Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.3% | +12.5M shares |
| 1 year | +26% | +82.4M shares |
| 3 years | +73% | +166M shares |
LCID has 395M diluted shares, up 26% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | $2.2M |
| Q1 2020 | — |
SORA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.9% | +1.2M shares |
| 1 year | +23% | +4.7M shares |
SORA has the edge over LCID on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
LCID Net Leverage
LCID's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
SORA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2024 | 33.6x | High |
SORA's net debt is more than 20 years of its operating earnings (EBITDA).
LCID Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 32.9 | Neutral |
| Stochastic | 7.1 | Oversold |
LCID's weekly RSI is 33 (neutral) and its Stochastic is 7 (oversold).
SORA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.4 | Neutral |
| Stochastic | 37.5 | Neutral |
SORA's weekly RSI is 50 (neutral) and its Stochastic is 37 (neutral).
LCID PE vs Consumer Cyclical Sector
LCID has no meaningful PE right now: it lost money over the past year.
SORA PE vs Consumer Cyclical Sector
| Metric | SORA | Sector median | Relative |
|---|---|---|---|
| PE | 4.9x | 18x | 73% below |
| PE % | 71 | 17 | 54 pts above |
SORA is trading at 4.8x earnings, a 73% discount to the Consumer Cyclical sector's median of 18x, though its earnings don't support one.
LCID Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.53 | 7.9% below |
| 20 week MA | $4.88 | 33% below |
| 50 week MA | $7.33 | 56% below |
| 100 week MA | $15.4 | 79% below |
| 200 week MA | $31.9 | 90% below |
SORA has stronger trend alignment. LCID is above 0 of 5 weekly averages versus SORA above 3 of 3.
SORA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.34 | 3.8% above |
| 20 week MA | $2.18 | 11% above |
| 50 week MA | $2.37 | 2.5% above |
SORA is in an uptrend: it's above all three of its weekly moving averages, and 2.5% above its 50-week average.
LCID Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $98.9 | $100.4 | +1.5% |
| 2021 | $100.4 | $376.4 | +275% |
| 2022 | $376.4 | $67.0 | -82% |
| 2023 | $67.0 | $42.1 | -37% |
| 2024 | $42.1 | $32.0 | -24% |
| 2025 | $32.0 | $11.4 | -64% |
| 2026 YTD | $11.4 | $3.25 | -72% |
LCID has finished four years in a row lower, and it's down 72% so far in 2026.
SORA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $10.3 | $3.43 | -67% |
| 2026 YTD | $3.43 | $2.43 | -29% |
SORA has the edge over LCID on returns for 2026, with the stronger performance.